Literature DB >> 31633488

Immunohistochemistry for PRAME in the Distinction of Nodal Nevi From Metastatic Melanoma.

Cecilia Lezcano1, Melissa Pulitzer, Andrea P Moy, Travis J Hollmann, Achim A Jungbluth, Klaus J Busam.   

Abstract

The distinction of metastatic melanoma from melanocytic nevi in lymph nodes can on occasion be difficult. As diffuse immunohistochemical (IHC) PRAME (PReferentially expressed Antigen in MElanoma) expression is detected in the majority of primary and metastatic melanomas, but rarely in nevi, we reasoned that PRAME could be a useful adjunct marker for the diagnosis of melanocytes in lymph nodes. In this study, we examined 45 nodal melanocytic deposits comprising 30 nodal nevi and 15 melanoma metastases. The latter were diagnostically not straightforward because they either coexisted with nodal nevi or were present in perinodal fibrous tissue. All nodal nevi (30/30) were negative for PRAME, whereas all melanoma metastases (15/15) were diffusely positive for PRAME IHC. We additionally report the novel use of a PRAME/Melan A dual-label immunostain. Our results show that PRAME IHC may be useful in the assessment of diagnostically challenging nodal melanocytic deposits, such as intraparenchymal nodal nevi, metastases confined to the capsular fibrous tissue, or in the setting of small metastases coexisting with a nodal nevus in the same lymph node.

Entities:  

Mesh:

Substances:

Year:  2020        PMID: 31633488      PMCID: PMC7071962          DOI: 10.1097/PAS.0000000000001393

Source DB:  PubMed          Journal:  Am J Surg Pathol        ISSN: 0147-5185            Impact factor:   6.298


  21 in total

1.  Characterization of an antigen that is recognized on a melanoma showing partial HLA loss by CTL expressing an NK inhibitory receptor.

Authors:  H Ikeda; B Lethé; F Lehmann; N van Baren; J F Baurain; C de Smet; H Chambost; M Vitale; A Moretta; T Boon; P G Coulie
Journal:  Immunity       Date:  1997-02       Impact factor: 31.745

Review 2.  The cancer testis antigen PRAME as a biomarker for solid tumor cancer management.

Authors:  Steve Goodison; Virginia Urquidi
Journal:  Biomark Med       Date:  2012-10       Impact factor: 2.851

3.  A103: An anti-melan-a monoclonal antibody for the detection of malignant melanoma in paraffin-embedded tissues.

Authors:  A A Jungbluth; K J Busam; W L Gerald; E Stockert; K A Coplan; K Iversen; D P MacGregor; L J Old; Y T Chen
Journal:  Am J Surg Pathol       Date:  1998-05       Impact factor: 6.394

4.  Histomorphologic assessment and interobserver diagnostic reproducibility of atypical spitzoid melanocytic neoplasms with long-term follow-up.

Authors:  Pedram Gerami; Klaus Busam; Alistair Cochran; Martin G Cook; Lyn M Duncan; David E Elder; Douglas R Fullen; Joan Guitart; Philip E LeBoit; Martin C Mihm; Victor G Prieto; Michael S Rabkin; Richard A Scolyer; Xiaowei Xu; Sook Jung Yun; Roxana Obregon; Pedram Yazdan; Chelsea Cooper; Bing Bing Weitner; Alfred Rademaker; Raymond L Barnhill
Journal:  Am J Surg Pathol       Date:  2014-07       Impact factor: 6.394

5.  Diagnostic utility of dual 5-hydroxymethylcytosine/Melan-A immunohistochemistry in differentiating nodal nevus from metastatic melanoma: An effective first-line test for the workup of sentinel lymph node specimen.

Authors:  Andrew B Siref; Carissa A T Huynh; Bonnie L Balzer; David P Frishberg; Richard Essner; Wonwoo Shon
Journal:  J Cutan Pathol       Date:  2019-01-31       Impact factor: 1.587

6.  Diagnostic utility of neural stem and progenitor cell markers nestin and SOX2 in distinguishing nodal melanocytic nevi from metastatic melanomas.

Authors:  Pei-Ling Chen; Wei-Shen Chen; Jianping Li; Anne C Lind; Dongsi Lu
Journal:  Mod Pathol       Date:  2012-08-17       Impact factor: 7.842

7.  Fatty Acid Synthase and Acetyl-CoA Carboxylase Are Expressed in Nodal Metastatic Melanoma But Not in Benign Intracapsular Nodal Nevi.

Authors:  Jad Saab; Maria Laureana Santos-Zabala; Massimo Loda; Edward C Stack; Travis J Hollmann
Journal:  Am J Dermatopathol       Date:  2018-04       Impact factor: 1.533

8.  Intraparenchymal nevus cell aggregates in lymph nodes: a possible diagnostic pitfall with malignant melanoma and carcinoma.

Authors:  David A Biddle; Harry L Evans; Bonnie L Kemp; Adel K El-Naggar; Jeff D Harvell; Wain L White; Sammy S Iskandar; Victor G Prieto
Journal:  Am J Surg Pathol       Date:  2003-05       Impact factor: 6.394

9.  Nodal nevi and cutaneous melanomas.

Authors:  K F Carson; D R Wen; P X Li; A M Lana; C Bailly; D L Morton; A J Cochran
Journal:  Am J Surg Pathol       Date:  1996-07       Impact factor: 6.394

10.  Diagnostic utility of IMP3 in segregating metastatic melanoma from benign nevi in lymph nodes.

Authors:  Mark J Mentrikoski; Linglei Ma; Jennifer G Pryor; Loralee A McMahon; Qi Yang; Betsy O Spaulding; Glynis A Scott; Hanlin L Wang; Haodong Xu
Journal:  Mod Pathol       Date:  2009-09-04       Impact factor: 7.842

View more
  9 in total

1.  Genetic investigation of nodal melanocytic nevi in cases of giant congenital melanocytic nevus.

Authors:  Y Cao; X Yang; Y-M Lai; L Jia; X-T Diao; Q Zhuang; D-M Lin
Journal:  Histol Histopathol       Date:  2020-07-30       Impact factor: 2.303

Review 2.  Cutaneous Melanomas: A Single Center Experience on the Usage of Immunohistochemistry Applied for the Diagnosis.

Authors:  Costantino Ricci; Emi Dika; Francesca Ambrosi; Martina Lambertini; Giulia Veronesi; Corti Barbara
Journal:  Int J Mol Sci       Date:  2022-05-25       Impact factor: 6.208

3.  HMB45/PRAME, a Novel Double Staining for the Diagnosis of Melanocytic Neoplasms: Technical Aspects, Results, and Comparison With Other Commercially Available Staining (PRAME and Melan A/PRAME).

Authors:  Marco Grillini; Costantino Ricci; Vincenzo Pino; Silvia Pedrini; Michelangelo Fiorentino; Barbara Corti
Journal:  Appl Immunohistochem Mol Morphol       Date:  2022-01-01

Review 4.  Molecular Biomarkers for Melanoma Screening, Diagnosis and Prognosis: Current State and Future Prospects.

Authors:  Dekker C Deacon; Eric A Smith; Robert L Judson-Torres
Journal:  Front Med (Lausanne)       Date:  2021-04-16

5.  Sensitive Immunofluorescent Detection of the PRAME Antigen Using a Practical Antibody Conjugation Approach.

Authors:  Ksenia A Sapozhnikova; Vsevolod A Misyurin; Dmitry Y Ryazantsev; Egor A Kokin; Yulia P Finashutina; Anastasiya V Alexeeva; Igor A Ivanov; Milita V Kocharovskaya; Nataliya A Tikhonova; Galina P Popova; Vera A Alferova; Alexey V Ustinov; Vladimir A Korshun; Vladimir A Brylev
Journal:  Int J Mol Sci       Date:  2021-11-27       Impact factor: 5.923

6.  PRAME protein expression in DICER1-related tumours.

Authors:  Paul S Thorner; Anne-Sophie Chong; Javad Nadaf; Naciba Benlimame; Paula Marrano; Rose Chami; Lili Fu; William D Foulkes
Journal:  J Pathol Clin Res       Date:  2022-03-16

7.  PRAME expression is similar in scar and desmoplastic melanoma.

Authors:  Jaclyn M Plotzke; Nicholas A Zoumberos; Steven M Hrycaj; Paul W Harms; Scott C Bresler; May P Chan
Journal:  J Cutan Pathol       Date:  2022-07-11       Impact factor: 1.458

Review 8.  Preferentially Expressed Antigen in Melanoma (PRAME) and Human Malignant Melanoma: A Retrospective Study.

Authors:  Gerardo Cazzato; Katia Mangialardi; Giovanni Falcicchio; Anna Colagrande; Giuseppe Ingravallo; Francesca Arezzo; Giovanna Giliberti; Irma Trilli; Vera Loizzi; Teresa Lettini; Sara Scarcella; Tiziana Annese; Paola Parente; Carmelo Lupo; Nadia Casatta; Eugenio Maiorano; Gennaro Cormio; Leonardo Resta; Domenico Ribatti
Journal:  Genes (Basel)       Date:  2022-03-19       Impact factor: 4.096

9.  Melanocytic nevi in sentinel lymph nodes: association with cutaneous nevi and clinical relevance in patients with cutaneous melanomas.

Authors:  Lutz Kretschmer; Viktor Schnabel; Christian Kromer; Christoph Bauer-Büntzel; Annika Richter; Felix Bremmer; Fabian Kück; Katharina Julius; Christina Mitteldorf; Michael P Schön
Journal:  J Cancer Res Clin Oncol       Date:  2022-01-20       Impact factor: 4.322

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.